To test feasibility of this approach for Alzheimer’s disease, we developed a cell morphology-based drug screen centred on the risk gene, SORL1 (which encodes the protein SORLA). The gene discussed is SORL1; the disease is early-onset autosomal dominant Alzheimer disease.